csa induces hyperglycemia and reduced glucose tolerance , and causes a decrease in immunoreactive insulin and an increase of somatostatin and pancreatic polypeptide ( pp ) immunoreactivities , leaving glucagon immunoreactivity unaffected .
C0020456
hyperglycemia
C0017725
glucose